Summary of Study ST000578

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000384. The data can be accessed directly via it's Project DOI: 10.21228/M8DP41 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST000578
Study TitleExperiment HuA: Metabolomics of plasma samples from humans infected with Plasmodium vivax strain.
Study TypeLongitudinal study and treatment of multiple individuals with Chloroquine
Study SummaryPatients with vivax malaria were enrolled in this study from June 2011 to December 2012 at the Fundacão de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD), an infectious disease referral center located in Manaus, Western Brazilian Amazon. This study, which required a 42-day follow-up period, was approved by the FMT-HVD Institutional Review Board and the Brazilian National Ethics Committee (CONEP) (IRB approval #: CAAE: 12516713.8.0000.0005). All protocols and documentation were reviewed and sample shipments approved by the Emory IRB. Male and female patients were eligible for inclusion if aged 6 months to 60 years, bodyweight >=5 kg, presenting a blood parasite density from 250 to 100,000 parasites/microliter and axillary temperature >=37.5°C or history of fever in the last 48 hours. Exclusion criteria were: use of antimalarials in the previous 30 days, refusal to be followed up for 42 days and any clinical complication. Patients received supervised treatment with 25 mg/kg of chloroquine (CQ) phosphate over a 3-day period (10 mg/kg on day 0 and 7.5 mg/kg on days 1 and 2). Primaquine (0.5 mg/kg per day for 7 days) was prescribed at the end of the 42-day follow-up period. Patients who vomited the first dose within 30 minutes after drug ingestion were re-treated with the same dose. Patients were evaluated on days 0, 1, 2, 3, 7, 14, 28 and 42 and, if they felt ill, at any time during the study period. Blood smear readings, complete blood counts, and diagnostic polymerase chain reaction (PCR) amplifications were performed at all time points. Three aliquots of 100 µL of whole blood from the day of a recurrence were spotted onto filter paper for later analysis by high performance liquid chromatography (HPLC) to estimate the levels of CQ and desethylchloroquine (DCQ) as previously described. In this study, CQ-resistance with parasitological failure was defined as parasite recurrence in the presence of plasma concentrations of CQ and DSQ higher than 100 ng/mL and microsatellite analysis revealing the presence of the same clonal nature at diagnosis and recurrence. The CQ-sensitive control group consisted of patients with no parasitemia recurring during follow-up period. A group of 20 healthy individuals from Brazil was used as non-malarial control group. Within the MaHPIC, this project is known as ‘Experiment HuA’. This dataset was produced by Dean Jones at Emory University.
Institute
Emory University
DepartmentSchool of Medicine, Vaccine Center at Yerkes
Last NameGalinksi
First NameMary
AddressEmory University, Yerkes National Primate Research Center, 954 Gatewood Rd, Room 003, Atlanta, GA 30329
Emailmahpic@emory.edu
PhoneNone
Submit Date2017-02-20
Num Groups273
Total Subjects220
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2017-07-10
Release Version1
Mary Galinksi Mary Galinksi
https://dx.doi.org/10.21228/M8DP41
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Current Malaria Infection Prior Malaria Infection Chloroquine Resistance
SA0304449991200046None N/A N/A
SA0304459991200047None N/A N/A
SA0304469991200048None N/A N/A
SA0304479991200045None N/A N/A
SA0304489991200049None N/A N/A
SA0304499991200042None N/A N/A
SA0304509991200043None N/A N/A
SA0304519991100022None N/A N/A
SA0304529991200050None N/A N/A
SA0304539991200055None N/A N/A
SA0304549991200056None N/A N/A
SA0304559991200054None N/A N/A
SA0304569991200053None N/A N/A
SA0304579991200051None N/A N/A
SA0304589991200052None N/A N/A
SA0304599991100021None N/A N/A
SA0304602129347None N/A N/A
SA0304612129340None N/A N/A
SA030462853678None N/A N/A
SA0304632129343None N/A N/A
SA0304642129339None N/A N/A
SA0304652129337None N/A N/A
SA0304662129341None N/A N/A
SA0304672129336None N/A N/A
SA0304682127215None N/A N/A
SA0304692129345None N/A N/A
SA0304702129338None N/A N/A
SA0304712129335None N/A N/A
SA0304722129346None N/A N/A
SA0304732129344None N/A N/A
SA0304742129342None N/A N/A
SA0304759991200057None N/A N/A
SA0304769991200044None N/A N/A
SA0304779991200041None N/A N/A
SA0304789991200062None N/A N/A
SA0304799991200059None N/A N/A
SA0304809991200058None N/A N/A
SA0304819991200061None N/A N/A
SA0304829991200060None N/A N/A
SA0304832016026None NO N/A
SA0304842016019None NO N/A
SA0304852016020None NO N/A
SA0304862016025None NO N/A
SA0304872016024None NO N/A
SA0304882016021None NO N/A
SA0304892016022None NO N/A
SA0304902016015None NO N/A
SA0304912016011None NO N/A
SA0304922016010None NO N/A
SA0304932016008None NO N/A
SA0304942016007None NO N/A
SA0304952016013None NO N/A
SA0304962016012None NO N/A
SA0304972016014None NO N/A
SA0304982016009None YES N/A
SA0304992016016None YES N/A
SA0305002016018None YES N/A
SA0305012016023None YES N/A
SA0305022016017None YES N/A
SA0305032008652P.Vivax N/A Resistant
SA0305042008613P.Vivax N/A Resistant
SA0305052008676P.Vivax N/A Resistant
SA0305062008629P.Vivax N/A Resistant
SA0305072008625P.Vivax N/A Resistant
SA0305082009263P.Vivax N/A Resistant
SA0305092008674P.Vivax N/A Resistant
SA0305102009255P.Vivax N/A Resistant
SA0305112009203P.Vivax N/A Resistant
SA0305122009249P.Vivax N/A Resistant
SA0305132009226P.Vivax N/A Resistant
SA0305142008699P.Vivax N/A Resistant
SA0305152008712P.Vivax N/A Resistant
SA0305162009267P.Vivax N/A Resistant
SA0305172008727P.Vivax N/A Resistant
SA0305182008660P.Vivax N/A Susceptible
SA0305192008654P.Vivax N/A Susceptible
SA0305202008651P.Vivax N/A Susceptible
SA0305212008631P.Vivax N/A Susceptible
SA0305222008627P.Vivax N/A Susceptible
SA0305232008710P.Vivax N/A Susceptible
SA0305242008618P.Vivax N/A Susceptible
SA0305252008603P.Vivax N/A Susceptible
SA0305262008622P.Vivax N/A Susceptible
SA0305272008623P.Vivax N/A Susceptible
SA0305282007278P.Vivax N/A Susceptible
SA0305292008624P.Vivax N/A Susceptible
SA0305302008628P.Vivax N/A Susceptible
SA0305312008621P.Vivax N/A Susceptible
SA0305322009254P.Vivax N/A Susceptible
SA0305332009253P.Vivax N/A Susceptible
SA0305342008722P.Vivax N/A Susceptible
SA0305352008680P.Vivax N/A Susceptible
SA0305362008679P.Vivax N/A Susceptible
SA0305372009261P.Vivax N/A Susceptible
SA0305382009265P.Vivax N/A Susceptible
SA0305392008678P.Vivax N/A Susceptible
SA0305402009262P.Vivax N/A Susceptible
SA0305412009266P.Vivax N/A Susceptible
SA0305422009233P.Vivax N/A Susceptible
SA0305432009109P.Vivax N/A Susceptible
Showing page 1 of 3     Results:    1  2  3  Next     Showing results 1 to 100 of 273
  logo